← Leaderboards
Ravinder Kaur
Rochester General Hospital (Ny)
$812,141
Attributed
$1,014,410
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $404.5K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,014,410 · 3
By mechanism
R21$440,000 · 1
R01$404,539 · 1
R03$169,871 · 1
Top collaborators
- Michael E Pichichero1 shared
Most similar at Rochester General Hospital (Ny)
Same institution · by research overlap
- Michael E Pichichero$8,990,191
- Dabin Ren$173,713
Others in their field
Other Emerging Leaders on “Immune Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$72,098,149
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Scott Hensley · University Of Pennsylvania$49,058,212
Research focus
Immune ResponsePreventSinusitisAntibody ResponseVaccinationPreventionOtitis MediaResponseImmunogenicityVaccinesMemoryAdultImmuneAntibodiesAcuteChildLipoproteinsAntigensMediatingCellsLipidsConjugate VaccinesImmunityConjunctivitis
Grant awards (5)
Haemophilus influenzae lipoprotein fusion vaccine and lipoprotein vaccine platform development$404,539
R01 · FY2025 · AI
Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae$200,000
R21 · FY2021 · AI · contact PI
Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae$240,000
R21 · FY2020 · AI · contact PI
Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine$85,043
R03 · FY2018 · HD · contact PI
Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine$84,828
R03 · FY2017 · HD · contact PI